Widely used:Recently Viewed
Clear All
$1,561 Mln
--
4.36
--
1.22
-16.53 %
--
--
--
-1219764
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Immunocore Holdings (IMCR)
| -54.46 | -13.77 | -13.63 | -35.52 | -6.74 | -- | -- |
|
BSE Sensex
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
Immunocore Holdings (IMCR)
| 19.71 | 66.68 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$1,561.09 Mln
$314.16 Mln
$1.90 Mln
$859.60 Mln
$472.95 Mln
High
$29.72 - 76.98
50,018,800
NASDAQ: IMCR
Abingdon
https://www.immunocore.com
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with... unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Address: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY Read more
The total asset value of Immunocore Holdings Ltd (IMCR) stood at $ 1,208 Mln as on 30-Jun-24
The share price of Immunocore Holdings Ltd (IMCR) is $31.11 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Immunocore Holdings Ltd (IMCR) has given a return of -6.74% in the last 3 years.
Immunocore Holdings Ltd (IMCR) has a market capitalisation of $ 1,561 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Immunocore Holdings Ltd (IMCR) is 4.36 times as on 02-Oct-2024, a 40% premium to its peers’ median range of 3.12 times.
Since, TTM earnings of Immunocore Holdings Ltd (IMCR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immunocore Holdings Ltd (IMCR) and enter the required number of quantities and click on buy to purchase the shares of Immunocore Holdings Ltd (IMCR).
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Address: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY
The CEO & director of Dr. Bahija Jallal Ph.D.. is Immunocore Holdings Ltd (IMCR), and CFO & Sr. VP is Dr. Bahija Jallal Ph.D..
There is no promoter pledging in Immunocore Holdings Ltd (IMCR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Immunocore Holdings Ltd (IMCR) | Ratios |
|---|---|
|
Return on equity(%)
|
-16.53
|
|
Operating margin(%)
|
-8.82
|
|
Net Margin(%)
|
-19.15
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Immunocore Holdings Ltd (IMCR) was $2 Mln.
$0.61
